La Jolla Pharmaceutical Company Closes Offering of Common Stock
La Jolla intends to use the net proceeds from the offering for general corporate purposes, including funding its ongoing and future clinical trials, and for general and administrative expenses.
The securities described above were offered pursuant to a shelf
registration statement (File No. 333-197092), including a base
prospectus, which was declared effective by the
La Jolla Pharmaceutical Company
George F. Tidmarsh, M.D., Ph.D.
President & Chief Executive Officer
Dennis M. Mulroy
Chief Financial Officer